Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients

Antiviral Therapy

Volumn 17, Issue 2, 2012, Pages 377-386

  Barth, Roos E ^a   Aitken, Susan C ^a   Tempelman, Hugo ^b   Geelen, Sibyl P ^c   Van Bussel, Erik M ^a   Hoepelman, Andy I M ^a   Schuurman, Rob ^a   Wensing, Annemarie M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Ndlovu Medical Centre   (South Africa)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SOUTH AFRICA; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 84860331359     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2010     Document Type: Article

References (34)

1. UNAIDS. Report on the global AIDS epidemic. (Updated 2010. Accessed 10 October 2011.) Available from http://www.unaids.org/globalreport/documents/ 20101123-GlobalReport-full-en.pdf
2. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
3. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371:1603-1611. (Pubitemid 351626844)
4. Barth RE, Schim van der Loeff M, Schuurman R, Hoepelman A, Wensing AMJ. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-166.
5. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
6. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. (Updated 2010. Accessed 10 October 2011.) Available from http://www.who.int/hiv/pub/arv/adult2010/en/index.html
7. WHO. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach. (Updated 2010. Accessed 10 October 2011.) Available from http://whqlibdoc.who.int/ publications/2010/9789241599801-eng.pdf
8. Kantor R, Diero L, Delong A, et al. Misclassification of firstline antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454-462.
9. Keiser O, MacPhail P, Boulle A, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009; 14:1220-1225.
10. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
11. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009; 49:1928-1935.
12. Soria A, Porten K, Fampou-Toundji JC, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009; 14:339-347.
13. Reynolds SJ, Kityo C, Mbamanya R, et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 2009; 14:293-297.
14. Barth RE, van der Meer JT, Hoepelman AI, et al. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis 2008; 27:977-984.
15. Aitken SC, Wallis A, Chu C, et al. Evaluation of an affordable assay for drug-resistance genotyping of all major HIV-1 subtypes. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 572.
16. Department of Health and Human Services. Los Alamos National Laboratory. HIV databases. HIV sequence database. 2005-2006. (Updated 26 January 2010. Accessed 10 October 2011.) Available from http://www.hiv.lanl.gov/content/ sequence/HIV/mainpage.html
17. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. (Updated 16 August 2010. Access 10 October 2011.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf
18. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-145.
19. Maillard A, Chapplain JM, Tribut O, et al. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitorexperienced patients. J Clin Virol 2007; 38:131-138. (Pubitemid 46074456)
20. Maggiolo F, Airoldi M, Callegaro A, et al. Prediction of virologic outcome of salvage antiretroviral treatment by different systems for interpreting genotypic HIV drug resistance. J Int Assoc Physicians AIDS Care (Chic) 2007; 6:87-93.
21. Liu TF, Shafer RW. Web resources for HIV type 1 genotypicresistance test interpretation. Clin Infect Dis 2006; 42:1608-1618.
22. Rosen SL, Stevens L, Sanne W, Fox IM. The net cost of incorporating resistance testing into HIV-treatment in South Africa. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 823.
23. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
24. Ndembi N, Goodall RL, Dunn DT, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudinelamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis 2010; 201:106-113.
25. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
26. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1449-1454.
27. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-484.
28. Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2007; 21:1405-1414. (Pubitemid 46988000)
29. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-4977.
30. Coutsinos D, Invernizzi C F, Xu H, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009; 83:2029-2033.
31. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-518.
32. Gutmann C, Cusini A, Gunthard HF, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment CD4-nadir. AIDS 2010; 24:2347-2354.
33. Meynard JL, Bouteloup V, Landman R, et al. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother 2010; 65:2436-2444.
34. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2:25-36. (Pubitemid 352019087)